Advanced Enzyme Tech
Healthcare
Advanced Enzyme Technologies Ltd
ADVENZYMES NSE
₹278.40 +4.15 (+1.51%)
- P/E
- 18.79
Close 4 Nov 2026 ₹278.40 −32.60 −10.5% 1Y
Start ₹311.00
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 14.00%
- Debt to Equity
- 0.02
- EPS (TTM)
- ₹14.82
- Book Value
- ₹148.70
- Market Cap
- —
- P/E (TTM)
- 18.79
- P/B
- 1.87
- ROE
- 10.20%
- Dividend Yield
- 1.95%
- EBITDA
- ₹264 Cr
- 52W High
- ₹419.00
- 52W Low
- ₹246.80
- Day Range
- ₹271.05 – ₹285.00
- Volume
- 2,26,371
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
58 Good
Data confidence 100/100
Category scores
- Quality
- 67
- Strong
- Returns, margins, earnings quality 22% weight
- Valuation
- 79
- Strong
- Cheap vs sector & own history 24% weight
- Growth
- 43
- Weak
- Sales & profit trajectory 9% weight
- Financial Health
- 87
- Strong
- Solvency, leverage, coverage 9% weight
- Momentum
- 21
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 37
- Weak
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 40.9%
Weaknesses
2- The company has delivered a poor sales growth of 8.24% over past five years.
- Company has a low return on equity of 10.3% over last 3 years.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Neutral | 7 | 5 | 7 |
| Oscillators | Bullish | 1 | 5 | 3 |
| Moving Averages | Strong Bearish | 6 | 0 | 4 |
Oscillators
Bullish
Bearish
1
Neutral
5
Bullish
3
Overall
Neutral
Bearish
7
Neutral
5
Bullish
7
Moving Averages
Strong Bearish
Bearish
6
Neutral
0
Bullish
4
Key readings
- RSI (14)
- 55.92
- Neutral
- MACD (12,26,9)
- −2.61
- Bullish
- SMA (50)
- 280.95
- Bearish
- SMA (200)
- 308.67
- Bearish
As of
Analyst Rating
Based on 1 analysts
1 of 1 analyst rates Buy, 0 Hold, 0 Sell.
As of
BUY
1
100% HOLD
0
0% SELL
0
0% Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | +9.80% |
|---|---|
| 5Y | +8.24% |
| 3Y | +11.30% |
| 1Y | +17.11% |
| TTM | +12.28% |
Net profit
| 10Y | +8.49% |
|---|---|
| 5Y | +2.88% |
| 3Y | +18.71% |
| 1Y | +29.85% |
| TTM | +23.74% |
Operating cash flow
| 10Y | +5.38% |
|---|---|
| 5Y | −0.75% |
| 3Y | +3.89% |
| 1Y | +10.56% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | −16.27 pp |
|---|---|
| 5Y | −15.39 pp |
| 3Y | +1.62 pp |
| 1Y | +0.06 pp |
| TTM | −0.06 pp |
Revenue by year
| Mar 2017 | ₹329 Cr |
|---|---|
| Mar 2018 | ₹391 Cr |
| Mar 2019 | ₹420 Cr |
| Mar 2020 | ₹444 Cr |
| Mar 2021 | ₹502 Cr |
| Mar 2022 | ₹529 Cr |
| Mar 2023 | ₹541 Cr |
| Mar 2024 | ₹624 Cr |
| Mar 2025 | ₹637 Cr |
| Mar 2026 | ₹746 Cr |
Net profit by year
| Mar 2017 | ₹93.00 Cr |
|---|---|
| Mar 2018 | ₹94.00 Cr |
| Mar 2019 | ₹116 Cr |
| Mar 2020 | ₹133 Cr |
| Mar 2021 | ₹151 Cr |
| Mar 2022 | ₹124 Cr |
| Mar 2023 | ₹104 Cr |
| Mar 2024 | ₹137 Cr |
| Mar 2025 | ₹134 Cr |
| Mar 2026 | ₹174 Cr |
Analyst Forecasts
Forecast For
Mar 27 consensus · Price
₹370.00 +31.4% vs Sep 26
Reported High Mean Low
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 147 | 158 | 161 | 158 | 155 | 146 | 169 | 167 | 186 | 185 | 172 | 203 | 190 | 215 |
| Expenses | 103 | 107 | 107 | 102 | 103 | 104 | 114 | 122 | 129 | 124 | 123 | 140 | 139 | 142 |
| Operating Profit | 44 | 51 | 54 | 55 | 51 | 42 | 55 | 46 | 56 | 60 | 49 | 63 | 51 | 72 |
| OPM % | 30% | 32% | 33% | 35% | 33% | 29% | 33% | 27% | 30% | 33% | 29% | 31% | 27% | 34% |
| Other Income | 7 | 6 | 14 | −6 | 7 | 10 | 8 | 9 | 9 | 10 | 20 | 7 | 13 | 9 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 11 |
| PBT | 41 | 48 | 59 | 40 | 49 | 42 | 53 | 43 | 55 | 60 | 58 | 60 | 54 | 69 |
| Tax % | 29% | 27% | 28% | 25% | 28% | 21% | 27% | 38% | 26% | 25% | 26% | 24% | 28% | 26% |
| Net Profit | 29 | 35 | 42 | 30 | 35 | 33 | 39 | 27 | 40 | 45 | 43 | 45 | 39 | 51 |
| EPS (₹) | 2.58 | 3.08 | 3.74 | 2.53 | 3.05 | 2.94 | 3.37 | 2.37 | 3.57 | 3.87 | 3.8 | 3.84 | 3.31 | — |
Sep 2026: from the results filed on 31 Oct 2026, ahead of the full statement, so some rows are blank.
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 222 | 293 | 329 | 391 | 420 | 444 | 502 | 529 | 541 | 624 | 637 | 746 | 750 |
| Expenses | 131 | 155 | 177 | 226 | 236 | 241 | 269 | 327 | 382 | 418 | 441 | 515 | 526 |
| Operating Profit | 91 | 138 | 152 | 165 | 184 | 203 | 232 | 203 | 158 | 206 | 196 | 230 | 224 |
| OPM % | 41% | 47% | 46% | 42% | 44% | 46% | 46% | 38% | 29% | 33% | 31% | 31% | 30% |
| Other Income | 1 | −3 | 3 | 1 | 5 | 6 | 9 | 6 | 21 | 21 | 33 | 46 | 50 |
| Interest | 9 | 8 | 4 | 9 | 5 | 4 | 3 | 3 | 3 | 4 | 5 | 2.63 | 2 |
| Depreciation | 9 | 9 | 13 | 18 | 21 | 26 | 28 | 35 | 35 | 35 | 37 | 40 | 40 |
| PBT | 74 | 118 | 137 | 139 | 162 | 179 | 210 | 171 | 140 | 188 | 187 | 233 | 231 |
| Tax % | 31% | 35% | 32% | 33% | 28% | 26% | 28% | 28% | 26% | 27% | 28% | 25% | — |
| Net Profit | 51 | 77 | 93 | 94 | 116 | 133 | 151 | 124 | 104 | 137 | 134 | 174 | 172 |
| EPS (₹) | 4.6 | 6.97 | 8.2 | 8.07 | 9.95 | 11.58 | 13.09 | 10.7 | 9.45 | 11.92 | 11.72 | 15.07 | 14.82 |
| Div. Payout % | 4% | 3% | 5% | 6% | 6% | 5% | 7% | 9% | 11% | 43% | 44% | 36% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 |
| Reserves | 188 | 256 | 442 | 537 | 657 | 817 | 948 | 1,066 | 1,213 | 1,302 | 1,398 | 1,610 |
| Borrowings | 115 | 101 | 54 | 67 | 35 | 28 | 23 | 35 | 34 | 47 | 39 | 32 |
| Other Liabilities | 92 | 71 | 65 | 102 | 91 | 104 | 153 | 137 | 142 | 150 | 151 | 170 |
| Total Liabilities | 417 | 450 | 583 | 727 | 805 | 971 | 1,146 | 1,260 | 1,411 | 1,521 | 1,611 | 1,834 |
| Fixed Assets | 287 | 285 | 421 | 491 | 495 | 563 | 601 | 619 | 649 | 650 | 679 | 692 |
| CWIP | 5 | 7 | 8 | 11 | 10 | 10 | 10 | 15 | 22 | 41 | 22 | 51 |
| Investments | 0 | 0 | 0 | 0 | 111 | 124 | 121 | 102 | 360 | 403 | 480 | 584 |
| Other Assets | 125 | 158 | 153 | 226 | 188 | 275 | 413 | 524 | 380 | 427 | 430 | 507 |
| Total Assets | 417 | 450 | 583 | 727 | 805 | 971 | 1,146 | 1,260 | 1,411 | 1,521 | 1,611 | 1,834 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 54 | 93 | 107 | 116 | 129 | 141 | 163 | 122 | 140 | 141 | 142 | 157 |
| Investing | −15 | −10 | −60 | −60 | −124 | −43 | −27 | 2 | −286 | −65 | −89 | −72 |
| Financing | −36 | −63 | −65 | −2 | −43 | −39 | −26 | −48 | −26 | −59 | −73 | −70 |
| Net Cash Flow | 2 | 21 | −18 | 54 | −38 | 60 | 109 | 75 | −171 | 17 | −20 | 15 |
| Free Cash Flow | 42 | 88 | 97 | 105 | 116 | 90 | 143 | 95 | 102 | 94 | 108 | 105 |
| CFO/EBITDA | 88 | 88 | 105 | 97 | 70 | 94 | 94 | 87 | 112 | 93 | 103 | 96 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 61 | 52 | 55 | 55 | 51 | 61 | 63 | 61 | 68 | 58 | 66 | 71 |
| Inventory Days | 403 | 358 | 352 | 339 | 363 | 361 | 346 | 402 | 343 | 375 | 378 | 335 |
| Days Payable | 89 | 68 | 57 | 78 | 46 | 43 | 56 | 60 | 67 | 40 | 47 | 76 |
| Cash Conversion Cycle | 374 | 342 | 351 | 315 | 369 | 379 | 353 | 404 | 344 | 393 | 397 | 331 |
| Working Capital Days | −43 | 3 | 76 | 47 | 72 | 90 | 94 | 116 | 109 | 102 | 112 | 116 |
| ROCE % | 25% | 36% | 31% | 25% | 24% | 22% | 22% | 16% | 12% | 15% | 13% | 14% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Advanced Enzyme Tech insights
65 extracted metrics across FY11–FY27.
Documents
- Q1 FY27 concall · Aug 2026Transcript PPT Recording
- Q4 FY26 concall · May 2026Transcript PPT
- Concall · Mar 2026Recording
- Q3 FY26 concall · Feb 2026Transcript PPT Recording
- Q2 FY26 concall · Nov 2025Transcript PPT
- 30 Apr 2026
- 13 Feb 2026
- 30 Jan 2025
- 28 Dec 2023
- 31 Oct 2022
- General announcements 3 Nov 2026
- General announcements 31 Oct 2026
Frequently Asked Questions about Advanced Enzyme Tech
What does Advanced Enzyme Technologies Ltd do?
Advanced Enzyme Technologies Limited is engaged in the business of manufacturing and sales of enzymes.
Where is Advanced Enzyme Technologies Ltd (ADVENZYMES) listed?
Advanced Enzyme Technologies Ltd trades as ADVENZYMES on the NSE and under code 540025 on the BSE.
Which sector does Advanced Enzyme Technologies Ltd belong to?
Advanced Enzyme Technologies Ltd is classified under the Healthcare sector, in the Biotechnology industry.
What is the PE ratio of Advanced Enzyme Technologies Ltd?
Advanced Enzyme Technologies Ltd trades at a PE ratio of 18.79 as of 4 Nov 2026, on earnings per share of ₹14.82, against a book value of ₹148.7 per share.
What is the 52-week high and low of Advanced Enzyme Technologies Ltd?
Over the last 52 weeks Advanced Enzyme Technologies Ltd has traded between ₹246.8 and ₹419 as of 4 Nov 2026.
Does Advanced Enzyme Technologies Ltd pay dividends?
Advanced Enzyme Technologies Ltd has a dividend yield of 1.95%.
What is the Return on Equity (ROE) of Advanced Enzyme Technologies Ltd?
Advanced Enzyme Technologies Ltd reported a return on equity of 10.20%. Its debt-to-equity ratio is 0.02.
Company Information
Advanced Enzyme Technologies Limited is engaged in the business of manufacturing and sales of enzymes.
Website advancedenzymes.com
CEO Mr. Beni Prasad Rauka CA
Employees 338
Listed 1 Aug 2016
Face Value ₹2
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ADVENZYMES.md for Advanced Enzyme Technologies Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.